Allergy Therapeutics(DE:HHU)
€0.030.00 (-15.38%)
DE:HHU
Allergy Therapeutics stock drug pipeline
€0.03
At close:0.00 (-15.38%)
Allergy Therapeutics (HHU) Drug Pipeline
1 Followers
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Allergy Therapeutics (DE:HHU) have in its pipeline
Allergy Therapeutics DE:HHU is currently developing the following drugs: Pq Grass, Vlp Peanut, Grass Mata Mpl, Grass Mata Mpl 5100Su, Grass Mata Mpl 10200Su, Grass Mata Mpl 18200Su, Grass Mata 5100Su, Grass Mata Mpl 10200, Grass Mata Mpl 18200, Tree Mata Mpl Or Tree Mata, Ragweedmatampl, Grass Matampl, Tree Mata Mpl - Therapeutic Regimen, Tree Mata Mpl - Intermediate Dose, Tree Mata Mpl - Low Dose. These drug candidates are in various stages of clinical development as the company works toward FDA approval.

